Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photoimmunotherapy and Anti-PD1 in Refractory Inoperable and Metastatic NSCLC
NCT06943664Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab sarotalocan sodium in non-small cell lung cancer (NSCLC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Overall Response Rate up to 2 years. Planned start Aug 2026; status: withdrawn.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06943664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943664.